Cellular Biomedicine Group, Inc.:
Cellular Biomedicine Group (NASDAQ: CBMG), a clinical-stage biopharma, will bring the first marketed CAR-T cell therapy, Kymriah, to China (the second largest healthcare market) with its strategic collaboration with Novartis. This validates CBMG's in-house cell manufacturing capabilities developed in partnership with General Electric and Thermo Fisher. CBMG's proprietary immuno-oncology pipeline includes BCMA, CD22, TCR-T for HCC and TIL for the treatment of NSCLC and other solid tumors.
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by